[1] Kjellen L, Lindahl U. Proteoglycans:structures and interactions[J] . Annu Rev Biochem, 1991, 60:443-475.
[2] Iozzo RV. Matrix proteoglycans:from molecular design to cellular function[J] . Annu Rev Biochem, 1998, 67:609-652.
[3] Capila I, Linhardt RJ. Heparin-protein interactions[J] . Angew Chem Int Ed Engl, 2002, 41:391-412.
[4] Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications[J] . Int Rev Cell Mol Biol, 2009, 276:105-159.
[5] Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis[J] . J Clin Invest, 2001, 108:341-347.
[6] Gray E, Mulloy B, Barrowcliffe TW. Heparin and low molecular-weight heparin[J] . Thromb Haemost, 2008, 99:807-818.
[7] Lindahl U. Heparan sulfate-protein interactions-a concept for drug design[J] . Thromb Haemost, 2007, 98:109-115.
[8] Voldavsky I, Friedmann Y, Elkin M, et al. Cloning of heparanase:gene cloning, expression and function in tumor progression and metastasis[J] . Nat Med, 1999, 5:793.
[9] Xu X, Ding J, Rao G, et al. Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endome-trium[J] . Hum Reprod, 2007, 22:927-937.
[10] Fux L, Ilan N, Sanderson RD, et al. Heparanase:busy at the cell surface[J] . Trends Biochem Sci, 2009, 34:511-519.
[11] Vreys V, David G. Mammalian heparanase:what is the message? [J] . Cell Mol Med, 2007, 11:427-452.
[12] Vlodavsky I, Beckhove P, Lerner I, et al. Significance of heparanase in cancer and inflammation[J] . Cancer Microenviron, 2012, 5:115-132.
[13] Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-mole-cular-weight heparin on cancer survival[J] . Thromb Haemost, 2007, 5:729-737.
[14] Lerner I, Baraz L, Pikarsky E, et al. Function of heparanase in prostate tumorigenesis:potential for therapy[J] . Clin Cancer Res, 2008, 14:668-676.
[15] Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer:correlation with tumor progression and patient surrival[J] . Neoplasia, 2006, 8:1055-1061.
[16] Nobuhisia T, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with malignant potential in human colon cancer[J] . Cancer Res Clin Oncol, 2005, 131:229-237.
[17] Raman K, Karuturi R, Swarup VP, et al. Discovery of novel sulfon-ated small molecules that inhibit vascular tube formation[J] . Bioorganic & Medicinal Chemistry Letters, 2012, 22:4467-4470.
[18] Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis [J] . Int J Biochem Cell Biol, 2006, 38:2018-2039.
[19] Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis[J] . Proc Natl Acad Sci USA, 2001, 98:3335-3357.
[20] Dredge K, Hammond E, Handley P, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models[J] . British Journal of Cancer, 2011, 104:635-642.
[21] Hammond E, Brandt R, Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcin-oma model[J] . PLoS One, 2012, 7:1-11.
[22] Dredge K, Hammond E, Davis K, et al. The PG500 series:novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy[J] . Invest New Drugs, 2010, 28:276-283.
[23] Levy-Adam F, Abboud-Jarrous G, Guerrini M, et al. Identification and characterization of heparin /heparan sulfate binding domains of the endoglycosidase heparanase[J] . J Biol Chem, 2005, 280:20457-20466.
[24] Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes[J] . J Cell Sci, 2004, 117:2249-2258.
[25] Marchetti D, Reiland J, Erwin B, et al. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues[J] . Int J Cancer, 2003, 104:167-174.
[26] Miao HQ, Elkin M, Aingorn E, et al. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligo deoxynucleo tides[J] . Int J Cancer, 1999, 83:424-431.
[27] Liu XY, Tang QS, Chen HC, et al. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity[J] . Int J Bio Sci, 2013, 9:564-577. |